医学
术前用药
临床试验
宫颈癌
不利影响
化疗
肿瘤科
药品
疾病
内科学
癌症
重症监护医学
外科
药理学
作者
Diane S. Aschenbrenner
标识
DOI：10.1097/01.naj.0000815420.91630.18
摘要
Tisotumab vedotin-tftv (Tivdak) has received accelerated approval to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.Ocular adverse effects occurred in 60% of patients in clinical trials. To minimize this risk, nurses should follow the guidelines for premedication and required eye care.
科研通智能强力驱动
Strongly Powered by AbleSci AI
不配.
西红柿炒番茄
哎嘿
kento
彭于彦祖
爱静静
pcr163
从容芮
starofjlu
maox1aoxin
寻道图强
iNk
Singularity
好困
ShowMaker
8R60d8
五十一笑声
互助遵法尚德
浅尝离白
丰盛的煎饼
皖公网安备34019202002308
